Entrada Therapeutics (TRDA) Competitors $7.27 +0.16 (+2.25%) Closing price 04:00 PM EasternExtended Trading$7.26 0.00 (-0.07%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. NAGE, AUPH, ELVN, ABCL, WVE, VERV, PAHC, AKBA, COLL, and NTLAShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Niagen Bioscience (NAGE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Its Competitors Niagen Bioscience Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics WAVE Life Sciences Verve Therapeutics Phibro Animal Health Akebia Therapeutics Collegium Pharmaceutical Intellia Therapeutics Niagen Bioscience (NASDAQ:NAGE) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations. Do analysts recommend NAGE or TRDA? Niagen Bioscience presently has a consensus price target of $19.50, suggesting a potential upside of 55.01%. Entrada Therapeutics has a consensus price target of $25.67, suggesting a potential upside of 253.05%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more volatility & risk, NAGE or TRDA? Niagen Bioscience has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Does the media favor NAGE or TRDA? In the previous week, Entrada Therapeutics had 6 more articles in the media than Niagen Bioscience. MarketBeat recorded 15 mentions for Entrada Therapeutics and 9 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.49 beat Entrada Therapeutics' score of 0.24 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of NAGE or TRDA? 15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by company insiders. Comparatively, 8.1% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is NAGE or TRDA more profitable? Entrada Therapeutics has a net margin of 14.39% compared to Niagen Bioscience's net margin of 13.07%. Niagen Bioscience's return on equity of 19.06% beat Entrada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience13.07% 19.06% 12.20% Entrada Therapeutics 14.39%5.84%4.61% Which has preferable earnings & valuation, NAGE or TRDA? Entrada Therapeutics has higher revenue and earnings than Niagen Bioscience. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$99.60M9.95$8.55M$0.1774.00Entrada Therapeutics$210.78M1.31$65.63M$0.818.98 SummaryEntrada Therapeutics beats Niagen Bioscience on 10 of the 17 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$269.85M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio8.9821.1726.1419.88Price / Sales1.31278.47414.67113.66Price / Cash4.4841.4736.1356.90Price / Book0.637.518.055.38Net Income$65.63M-$55.05M$3.15B$248.50M7 Day Performance2.97%2.45%1.85%2.97%1 Month Performance-10.69%7.33%4.81%6.02%1 Year Performance-48.07%5.38%34.86%20.39% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics3.3557 of 5 stars$7.27+2.3%$25.67+253.0%-50.3%$269.85M$210.78M8.98110Trending NewsInsider TradeNAGENiagen Bioscience1.4985 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.06B$99.60M80.24120AUPHAurinia Pharmaceuticals2.7144 of 5 stars$7.83+0.8%$11.50+46.9%+36.2%$1.05B$235.13M27.96300ELVNEnliven Therapeutics2.4691 of 5 stars$20.29-4.7%$39.60+95.2%-13.4%$1.05BN/A-10.5750Analyst ForecastHigh Trading VolumeABCLAbCellera Biologics2.2401 of 5 stars$3.33-2.3%$8.33+150.3%+25.5%$1.02B$28.83M-5.95500WVEWAVE Life Sciences4.5404 of 5 stars$6.96+5.9%$20.50+194.5%+24.4%$1.01B$108.30M-8.29240Positive NewsVERVVerve Therapeutics3.5023 of 5 stars$11.11+0.5%$14.75+32.8%+126.5%$985.92M$32.33M-5.27110High Trading VolumePAHCPhibro Animal Health3.5585 of 5 stars$24.46+2.4%$20.80-15.0%+56.2%$967.94M$1.02B31.361,940AKBAAkebia Therapeutics4.3431 of 5 stars$3.64-1.1%$6.75+85.4%+259.0%$966.50M$160.18M-17.33430News CoveragePositive NewsInsider TradeCOLLCollegium Pharmaceutical4.0324 of 5 stars$29.88+0.2%$43.75+46.4%-7.1%$958.49M$631.45M24.49210News CoverageNTLAIntellia Therapeutics4.6699 of 5 stars$9.23+0.3%$33.37+261.5%-56.0%$952.96M$57.88M-1.76600 Related Companies and Tools Related Companies Niagen Bioscience Alternatives Aurinia Pharmaceuticals Alternatives Enliven Therapeutics Alternatives AbCellera Biologics Alternatives WAVE Life Sciences Alternatives Verve Therapeutics Alternatives Phibro Animal Health Alternatives Akebia Therapeutics Alternatives Collegium Pharmaceutical Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
